Is UnitedHealth stock a buy after strong earnings?

In April 2025, UnitedHealth (NYSE: UNH) stock suffered a 50% collapse following a surprise earnings miss paired with weak guidance,  but the company’s fortunes might finally be fully reversing following the quarterly report published almost exactly one year later.

Indeed, after climbing approximately 20% in the last 30 days, UNH shares suddenly surged higher in the extended session ahead of the April 21 morning bell, rallying 7.89% from the Monday close of $323.48 to $349 at press time. 

The upswing was triggered by an exceptionally strong quarterly earnings report that revealed UnitedHealth beat analyst forecasts by a significant margin. Specifically, the firm’s revenue came in more than $2 billion higher than the expected $109.57 billion and at $111.72 billion.

Earnings per share (EPS) also offered a positive surprise, as they amounted to $7.23 instead of the expected $6.57.

Why UnitedHealth financials are set for additional improvements in 2026

Simultaneously, the latest quarterly earnings represent the latest in what is shaping up to be a series of positive developments both for UnitedHealth and for the entire healthcare insurance industry.

UNH stock already saw one rapid, 9% rise earlier in April, following a U.S. government decision to increase payments to private providers of Medicare Advantage plans. 

Shortly ahead of the announcement, UnitedHealth shares were changing hands at $281.63 and soared 14.97% in the subsequent two weeks to their latest closing price of $323.48.

Wall Street sets UNH stock price target for the next 12 months

By April 21, the market moves, government decisions, and business results all converged to help reinforce Wall Street’s prevailing view that UNH stock is an increasingly ‘Strong Buy.’

Indeed, along with boasting a positive recommendation based on the sum of all expert revisions issued in the last three months on the stock analysis platform TipRanks, UnitedHealth is expected to rally 13.98% to $368.70 in the coming 12 months.

Still, some room for caution remains between the healthcare giant’s track record in the financial market and its rapid rise, increasing the odds of a correction. Such an outlook is also reinforced by the fact that, out of the 12 Wall Street rating revisions, 33% have been ‘Neutral.’

On the flip side, all of the remaining eight have been positive with the highest 12-month price target – the one assigned by Bernstein on April 21 – even predicting a 27% rally to $411.

Featured image via Shutterstock